OTCPK:CSRM.Y

Stock Analysis Report

Executive Summary

Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices in Europe, the United States, the United Kingdom, and internationally.

Snowflake

Fundamentals

Established dividend payer with moderate growth potential.

Risks

  • Consort Medical has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Consort Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:CSRM.Y

-0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

n/a

OTCPK:CSRM.Y

9.1%

US Medical Equipment

2.0%

US Market

No trading data on CSRM.Y.

No trading data on CSRM.Y.


Share holder returns

CSRM.YIndustryMarket
7 Day0%-0.9%1.3%
30 Day-18.5%0.7%3.9%
90 Dayn/a4.4%3.4%
1 Yearn/a10.0%9.1%4.2%2.0%
3 Year-23.0%-26.3%70.7%65.5%47.2%37.6%
5 Year-20.4%-33.3%130.7%104.3%60.5%42.9%

Price Volatility Vs. Market

How volatile is Consort Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Consort Medical undervalued based on future cash flows and its price relative to the stock market?

24.06x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Consort Medical's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Consort Medical's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Consort Medical is good value based on earnings compared to the US Medical Equipment industry average.

Consort Medical is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Consort Medical is poor value based on expected growth next year.


Price Based on Value of Assets

Consort Medical is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Consort Medical expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

22.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Consort Medical's revenue is expected to grow by 3.6% yearly, however this is not considered high growth (20% yearly).

Consort Medical's earnings are expected to grow significantly at over 20% yearly.

Consort Medical's revenue growth is positive but not above the United States of America market average.

Consort Medical's earnings growth is expected to exceed the United States of America market average.

Consort Medical's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Consort Medical is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Consort Medical performed over the past 5 years?

12.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Consort Medical's year on year earnings growth rate has been positive over the past 5 years.

Consort Medical's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Consort Medical's 1-year earnings growth is negative, it can't be compared to the US Medical Equipment industry average.


Return on Equity

Consort Medical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Consort Medical used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Consort Medical has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Consort Medical's financial position?


Financial Position Analysis

Consort Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Consort Medical's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Consort Medical's level of debt (48.4%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (0% vs 48.4% today).

Debt is well covered by operating cash flow (30.6%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 13.3x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.1x debt.


Next Steps

Dividend

What is Consort Medical's current dividend yield, its reliability and sustainability?

2.70%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Consort Medical's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.48%).

Consort Medical's dividend is below the markets top 25% of dividend payers in United States of America (3.73%).

Dividends per share have been stable in the past 10 years.

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are covered by earnings (1.6x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (3.1x coverage).


Next Steps

Management

What is the CEO of Consort Medical's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Jon Glenn (49yo)

11.1yrs

Tenure

UK£1,825,000

Compensation

Mr. Jonathan M. Glenn, also known as Jon, has been the Chief Executive Offer of Consort Medical Plc at Bespak Europe Ltd. since December 5, 2007. Mr. Glenn has been a Director at Atlas Genetics Ltd. since ...


CEO Compensation Analysis

Jon's remuneration is higher than average for companies of similar size in United States of America.

Jon's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.3yrs

Average Tenure

The average tenure for the Consort Medical management team is less than 2 years, this suggests a new team.


Board Age and Tenure

6.6yrs

Average Tenure

53yo

Average Age

The tenure for the Consort Medical board of directors is about average.


Insider Trading

No 3 month insider trading information.


Ownership Breakdown


Management Team

  • Jon Glenn (49yo)

    CEO & Director

    • Tenure: 11.1yrs
    • Compensation: UK£1.83m
  • Colin Leeder

    Group Financial Controller

    • Tenure: 0yrs
  • Lisa King

    Director of Human Resources

    • Tenure: 10.4yrs
  • Keyvan Djamarani

    Business President of Bespak

    • Tenure: 1yrs
  • Paul Hayes (51yo)

    CFO & Executive Director

    • Tenure: 1.7yrs
    • Compensation: UK£719.00k
  • Andrew Jackson

    Group General Counsel & Company Secretary

    • Tenure: 0.4yrs
  • Manja Boerman

    Business President of Aesica

    • Tenure: 1yrs

Board Members

  • Peter Fellner (75yo)

    Chairman

    • Tenure: 9.7yrs
    • Compensation: UK£138.33k
  • William Jenkins (71yo)

    Senior Independent Director

    • Tenure: 7.3yrs
    • Compensation: UK£56.42k
  • Ian Nicholson (58yo)

    Non-Executive Director

    • Tenure: 6.6yrs
    • Compensation: UK£46.42k
  • Steve Crummett (53yo)

    Non-Executive Director

    • Tenure: 6.6yrs
    • Compensation: UK£48.92k
  • Drew Hosty (53yo)

    Non Executive Director

    • Tenure: 4.5yrs
    • Compensation: UK£41.42k
  • Jon Glenn (49yo)

    CEO & Director

    • Tenure: 11.1yrs
    • Compensation: UK£1.83m
  • Paul Hayes (51yo)

    CFO & Executive Director

    • Tenure: 1.7yrs
    • Compensation: UK£719.00k
  • Maria Ginman-Horrell (52yo)

    Non-Executive Director

    • Tenure: 3.9yrs
    • Compensation: UK£41.42k

Company Information

Consort Medical plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Consort Medical plc
  • Ticker: CSRM.Y
  • Exchange: OTCPK
  • Founded: 1946
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£405.175m
  • Listing Market Cap: UK£528.238m
  • Shares outstanding: 49.11m
  • Website: https://www.consortmedical.com

Number of Employees


Location

  • Consort Medical plc
  • Breakspear Park
  • Suite B
  • Hemel Hempstead
  • Hertfordshire
  • HP2 4TZ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CSRTLSE (London Stock Exchange)YesOrdinary SharesGBGBPJan 1992
8C7BST (Boerse-Stuttgart)YesOrdinary SharesDEEURJan 1992
CSRTlBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPJan 1992
CSRM.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDJun 2003

Biography

Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life imp ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/01/25 02:35
End of Day Share Price2019/01/18 00:00
Earnings2018/10/31
Annual Earnings2018/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.